Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Study of Silymarin for Improving Hepatitis C|
- Serum aminotransferases (ALT, AST) [ Time Frame: at six months after admission ] [ Designated as safety issue: Yes ]The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission
- HCV-RNA [ Time Frame: at six months after admission ] [ Designated as safety issue: Yes ]The investigators measured serum HCV-RNA by Polymerase Chain Reaction (PCR) at six months after silymarin admission
|Study Start Date:||March 2006|
|Study Completion Date:||September 2006|
|Primary Completion Date:||September 2006 (Final data collection date for primary outcome measure)|
Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
Tab 210 mg, 630 mg, daily, six months.
Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01292161
|Iran, Islamic Republic of|
|Al-zahra university hospital|
|Isfahan, Iran, Islamic Republic of|
|Principal Investigator:||hamid kalantari, A.Professor||Associate Professor,Gasteroentrology department|